Cytomegalovirus in renal transplant recipients from living donors with and without valganciclovir prophylaxis and with immunosuppression based on anti-thymocyte globulin or basiliximab

Background: In our population, anti-thymocyte globulin (ATG) of 1 mg/Kg/day for 4 days is used; which permits not using valgancyclovir (VGC) prophylaxis in some renal transplant recipients (RTR) with moderate risk (R+), to reduce costs. This study aimed to determine the incidence and risk of develop...

Full description

Bibliographic Details
Main Authors: Jorge Andrade-Sierra, Alejandro Heredia-Pimentel, Enrique Rojas-Campos, Diana Ramírez Flores, José I. Cerrillos-Gutierrez, Alejandra G. Miranda-Díaz, Luis A. Evangelista-Carrillo, Petra Martínez-Martínez, Basilio Jalomo-Martínez, Eduardo Gonzalez-Espinoza, Benjamin Gómez-Navarro, Miguel Medina-Pérez, Juan José Nieves-Hernández
Format: Article
Language:English
Published: Elsevier 2021-06-01
Series:International Journal of Infectious Diseases
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S1201971221003428